ClinicalTrials.gg
RecruitingNCT07656922Updated Jun 18, 2026

Scapular Muscle Activation and Shoulder Performance in Migraine

An observational study in Migraine, Upper Extremity and Muscle Activity, sponsored by Ankara Yildirim Beyazıt University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Ankara Yildirim Beyazıt University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
50
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 92 studies in Migraine Disorders with a site in Turkey — 20 open to participants now, 25 under way, 3 of them phase 3. Migraine Disorders · Turkey.

Planned enrollment
20th of 23
50 · median 130
Started
2026
with 8 others
Observational
23 of 92
4 open now
Primary completion
2026-07
later than 16 of 24 live
Registered
92nd of 92
by date
Lead sponsor
4 of 92
Ankara Yildirim Beyazıt University

Among the 92 studies in Migraine Disorders with a site in Turkey, this one is the 20th largest by planned enrollment of the 23 observational ones that give a count, is one of 9 that started in 2026, is one of 23 observational ones, reaches primary completion later than 16 of the 24 other live ones, and was the 92nd registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

20 of the 92 studies in Migraine Disorders with a site in Turkey are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Migraine Disorders with a site in Turkey, or all of them as a file.
02

Study summary

Migraine is a significant health problem due to its high prevalence and substantial contribution to disability. Individuals with migraine have been reported to exhibit myofascial trigger points, increased pain sensitivity, and altered muscle activation patterns, particularly in the trapezius muscles. As the upper and middle trapezius muscles play critical roles in scapular stability and movement, alterations in these muscles may affect scapular orientation and upper extremity function. However, studies investigating the relationship between trapezius muscle activation, scapular orientation, and upper extremity performance in individuals with migraine are limited. Therefore, this study aimed to compare trapezius muscle activation, scapular orientation, and upper extremity performance between individuals with and without migraine. We hypothesized that individuals with migraine would exhibit altered upper and middle trapezius muscle activation, impaired scapular orientation, and reduced upper extremity performance compared with healthy controls.

03

Conditions studied

  • Migraine
  • Upper Extremity
  • Muscle Activity

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Adults diagnosed with migraine according to the ICHD-3 criteria

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18-55 years
  • Diagnosed with migraine by a neurologist according to the ICHD-3 criteria
  • Experiencing at least 3 migraine attacks per month
  • Willing to participate and provide written

Exclusion criteria

Exclusion Criteria:

  • Presence of other types of headache disorders
  • History of trauma, fracture, or surgery involving the cranio-cervical region, scapular region, or upper extremity
  • Presence of neurological or inflammatory rheumatic diseases
  • Presence of psychiatric disorders
  • Receiving physiotherapy or rehabilitation for migraine or the cervical, thoracic, or upper extremity regions within the past 6 months
  • Cognitive impairment affecting the understanding of test instructions
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Migraine
  • Control
06

What researchers measure

Primary outcomes

  1. Trapezius muscle activity

    Upper and middle trapezius muscle activations will be assessed on the dominant side using surface electromyography (sEMG). Following skin preparation, EMG sensors will be placed over the upper and middle trapezius muscles according to the recommendations of the Surface Electromyography for the Non-Invasive Assessment of Muscles (SENIAM). Resting muscle activity will be recorded prior to measurements to ensure signal quality. Muscle activations will first be recorded during maximal voluntary isometric contraction (MVIC) and subsequently during arm elevation in the scapular plane. EMG data will be analyzed using EMGworks software; signals will be filtered, processed using the root mean square (RMS) method, and normalized to each participant's MVIC values, expressed as %MVIC. Additionally, upper trapezius/middle trapezius activation ratios will be calculated, and muscle activation levels will be categorized according to predefined threshold values.

    Time frame: Single assessment at baseline

Secondary outcomes

  1. Scapular rotation

    Scapular upward rotation will be assessed using a digital inclinometer at shoulder elevation angles of 0°, 45°, 90°, and 135°. Participants will stand comfortably with the elbow extended and elevate the arm with the thumb pointing upward to the target angles. The inclinometer will be positioned over the scapular spine to measure scapular upward rotation at each angle. Three measurements will be obtained at each position with 30-second rest intervals, and the mean value will be used for analysis.

    Time frame: Single assessment at baseline

  2. Pain

    The pressure pain threshold of the upper trapezius muscle will be assessed using a digital algometer. Measurements will be performed at the midpoint between the C7 vertebra and the acromion using a 1-cm diameter rubber probe. Pressure will be gradually increased until the participant first reports pain or discomfort. Three measurements will be obtained with 30-second intervals, and the mean value (N/m²) will be used for analysis.

    Time frame: Single assessment at baseline

  3. Upper extremity performance

    Upper extremity mobility, stability, and proprioception in a closed kinetic chain will be assessed using the Upper Quarter Y-Balance Test. Participants will perform the test in a push-up position while reaching in the medial, inferolateral, and superolateral directions with the free hand. Reach distances will be recorded in centimeters and normalized to upper extremity length. Composite reach scores will also be calculated, with greater reach distances indicating better upper extremity dynamic balance and function.

    Time frame: Single assessment at baseline

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Jul 2026, 3 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2026
First posted
Jun 18, 2026
StartActual
Apr 1, 2026
Primary completionEst.
Jul 1, 2026
CompletionEst.
Jul 15, 2026
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07656922
Responsible party
Sponsor
First posted
Jun 18, 2026
Start date
Apr 1, 2026
Primary completion
Jul 1, 2026 (estimated)
Completion
Jul 15, 2026 (estimated)
Last update
Jun 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion